Snapshot from Sep 17, 2026 at 07:00 UTC. For live data and tracking: View Live
Business product launch

Aurobindo launches generic Advair Diskus

Analysis based on 7 articles · First reported Aug 31, 2026 · Last updated Aug 31, 2026

Sentiment
40
Attention
4
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The launch opens a significant revenue stream for Aurobindo in the US inhalation market, estimated at $908 million, and intensifies competition with Cipla. It is expected to contribute to Aurobindo's goal of $2 billion US revenue, potentially pressuring GSK's branded Advair sales.

Pharmaceuticals

Aurobindo Pharma, through its wholly owned subsidiary Lannett Company Company LLC, has commercially launched a generic version of GSK plc's Advair Diskus (fluticasone propionate and salmeterol inhalation powder) in the US market in 100/50 mcg and 250/50 mcg strengths. This marks the first product from Aurobindo's inhalation pipeline to be commercialized in the US, reflecting its focus on expanding its portfolio of complex inhalation products. The drug is indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD). According to IQVIA, the US market for this product is approximately $908 million. The launch positions Aurobindo against Cipla, which recently received FDA approval for its generic version in all three strengths. Aurobindo's entry into the US inhalation market is part of its strategy to achieve $2 billion annual revenue from the US, following its $250 million acquisition of Lannett Company.

100 Lannett Company launched generic
stock
Aurobindo launched its first inhalation product in the US via Lannett Company, expanding its complex product portfolio and supporting its $2 billion US revenue target.
Importance 100.0 Sentiment 70.0
stock
Lannett Company, a wholly owned subsidiary, executed the launch, marking its first commercialized inhalation product and enhancing its revenue contribution.
Importance 90.0 Sentiment 75.0
stock
Cipla received FDA approval for its generic Advair, positioning it as a direct competitor to Aurobindo in the US respiratory market.
Importance 70.0 Sentiment 50.0
stock
GSK faces increased generic competition for its branded Advair Diskus, potentially eroding market share and revenue in the US.
Importance 60.0 Sentiment -20.0
govactor
The FDA's approval of Cipla's ANDA and its regulatory oversight of the market facilitate generic entry, shaping competitive dynamics.
Importance 50.0 Sentiment 0.0
cnt
The US market, valued at approximately $908 million, is the key commercial arena for this launch and generic competition.
Importance 40.0 Sentiment 0.0
stock
IQVIA provided market size data, quantifying the commercial opportunity for the generic product.
Importance 20.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.